Cystic Fibrosis Treatment Products

CSHCN Services Program

HHSC requires prior authorization for claims for Cayston, Kalydeco, Pulmozyme, and inhaled tobramycin. Prescribing providers complete and submit the Cystic Fibrosis Treatment Products Authorization Request (HHS Form 1143).

Pharmacy staff can perform an E1 eligibility verification transaction to find a person’s most current period of approval for Tobramycin.

  • Refer to the System Requirements section for information about claim transactions.
  • Refer to the E1 Transaction: Accepted Response to review the list of the expanded messages returned on the eligibility verification transaction.